Screener
Axsome Therapeutics AXSM Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $305,106 | $322,933 |
| Accounts receivable, net | 251,062 | 224,464 |
| Inventories, net | 31,515 | 27,938 |
| Prepaid and other current assets | 23,523 | 13,651 |
| Total current assets | 611,206 | 588,986 |
| Equipment, net | 567 | 562 |
| Right-of-use asset - operating lease | 20,014 | 20,858 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's inventories?
- Axsome Therapeutics (AXSM) reported inventories of $31.52M in Q1 2026.
- How has Axsome Therapeutics's inventories changed year-over-year?
- Axsome Therapeutics's inventories increased by 93.1% year-over-year, from $16.32M to $31.52M.
- What is the long-term trend for Axsome Therapeutics's inventories?
- Over 3 years (2022 to 2025), Axsome Therapeutics's inventories has grown at a 86.3% compound annual growth rate (CAGR), from $4.32M to $27.94M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about Axsome Therapeutics's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude